Eltoprazine Hydrochloride is primarily investigated for its potential therapeutic applications in treating various neurological and behavioral disorders. It is known to act as a serotonin receptor agonist, particularly targeting 5-HT1A and 5-HT1B receptors, which play a role in mood regulation and aggression control. This makes it a candidate for managing conditions like aggression, impulsivity, and irritability, often associated with psychiatric disorders such as Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and certain forms of autism. Additionally, it has been explored for its potential in reducing levodopa-induced dyskinesia in Parkinson's disease patients. Its ability to modulate serotonin pathways also suggests possible benefits in addressing anxiety and depression-related symptoms. Research continues to explore its efficacy and safety in these areas.